mci 9038 has been researched along with Cerebral Hemorrhage in 14 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (57.14) | 29.6817 |
2010's | 6 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barreto, AD; Cai, C; Ford, GA; Grotta, JC; Pedroza, C; Rahbar, MH; Shen, L; Tyson, J | 1 |
Barreto, AD; Berekashvili, K; Blackburn, S; Chen, PR; Dannenbaum, M; Grotta, JC; Misra, V; Shen, L; Soomro, J | 1 |
Chen, JL; Chen, W; Fan, RM; Han, C; Jiao, S; Li, G; Wang, CM; Xia, XP; Yao, ST; Zeng, YC | 1 |
Qu, F; Zhang, CD; Zhou, ZH | 1 |
Alexandrov, AV; Balucani, C; Barlinn, K; Barreto, AD; Chen, Z; Demchuk, AM; Garami, Z; Gonzales, NR; Grotta, JC; Lee, J; Lyden, P; Martin-Schild, S; Mikulik, R; Pandurengan, R; Rahbar, MH; Savitz, SI; Shen, L; Sisson, A; Sugg, RM; Tsivgoulis, G; Wu, TC | 1 |
Alexandrov, AV; Bavarsad Shahripour, R | 1 |
Hoff, JT; Hua, Y; Keep, RF; Kitaoka, T; Xi, G | 1 |
Hoff, JT; Hua, Y; Keep, RF; Kitaoka, T; Nagao, S; Xi, G | 1 |
Fujisawa, H; Koizumi, H; Nagatsuna, T; Nomura, S; Suehiro, E; Suzuki, M | 1 |
Akaike, A; Fujimoto, S; Katsuki, H; Kume, T | 1 |
Alexandrov, AV; Baraniuk, S; Garami, Z; Gonzales, NR; Grotta, JC; Matherne, DE; Mikulik, R; Moyé, LA; Pary, JK; Shaltoni, HM; Shaw, SG; Sugg, RM; Uchino, K | 1 |
Akaike, A; Fujimoto, S; Katsuki, H; Kume, T; Ohnishi, M; Takagi, M | 1 |
Berens, KL; Brown, PM; Chopp, M; Lu, M; Morris, DC; Zhang, L; Zhang, ZG | 1 |
Hamada, R; Matsuoka, H | 1 |
2 review(s) available for mci 9038 and Cerebral Hemorrhage
Article | Year |
---|---|
Ancillary approaches to plasminogen activators.
Topics: Anticoagulants; Arginine; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Collateral Circulation; Drug Synergism; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hypothermia, Induced; Low-Level Light Therapy; Pipecolic Acids; Plasminogen Activators; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Sulfonamides; Thrombolytic Therapy; Tirofiban; Tyrosine; Ultrasonic Therapy; Vasodilator Agents | 2012 |
Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention?
Topics: Antithrombins; Arginine; Brain; Brain Edema; Cerebral Hemorrhage; Humans; Neurons; Pilot Projects; Pipecolic Acids; Sulfonamides; Survival Rate; Thrombin; Treatment Outcome | 2002 |
2 trial(s) available for mci 9038 and Cerebral Hemorrhage
Article | Year |
---|---|
Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).
Topics: Aged; Aged, 80 and over; Antithrombins; Arginine; Brain Ischemia; Cerebral Hemorrhage; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pipecolic Acids; Severity of Illness Index; Stroke; Sulfonamides; Tissue Plasminogen Activator | 2017 |
Argatroban tPA stroke study: study design and results in the first treated cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arginine; Cerebral Hemorrhage; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pipecolic Acids; Prospective Studies; Recombinant Proteins; Research Design; Stroke; Sulfonamides; Tissue Plasminogen Activator; Treatment Outcome | 2006 |
10 other study(ies) available for mci 9038 and Cerebral Hemorrhage
Article | Year |
---|---|
Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study).
Topics: Aged; Aged, 80 and over; Arginine; Cerebral Hemorrhage; Combined Modality Therapy; Drug Therapy, Combination; Endovascular Procedures; Feasibility Studies; Fibrinolytic Agents; Humans; Incidence; Middle Aged; Pipecolic Acids; Platelet Aggregation Inhibitors; Postoperative Complications; Stroke; Sulfonamides; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2018 |
Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage.
Topics: Animals; Apoptosis; Arginine; Brain Edema; Cerebral Hemorrhage; Complement C5a; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Peptides, Cyclic; Pipecolic Acids; Platelet Aggregation Inhibitors; Receptor, Anaphylatoxin C5a; RNA, Messenger; Stroke; Sulfonamides; Tubulin | 2014 |
Systemic administration of argatroban inhibits protease-activated receptor-1 expression in perihematomal tissue in rats with intracerebral hemorrhage.
Topics: Animals; Arginine; Blotting, Western; Body Water; Brain Chemistry; Brain Edema; Cerebral Hemorrhage; Female; Male; Pipecolic Acids; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptor, PAR-1; Stereotaxic Techniques; Sulfonamides | 2011 |
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
Topics: Aged; Anticoagulants; Antithrombins; Arginine; Brain Ischemia; Cerebral Arteries; Cerebral Hemorrhage; Cerebral Veins; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Partial Thromboplastin Time; Pilot Projects; Pipecolic Acids; Stroke; Sulfonamides; Tissue Plasminogen Activator; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2012 |
Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage.
Topics: Animals; Antithrombins; Arginine; Brain; Brain Chemistry; Brain Edema; Cerebral Hemorrhage; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Hemoglobins; Infusions, Parenteral; Male; Microinjections; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Stereotaxic Techniques; Sulfonamides; Time Factors; Treatment Outcome; Water | 2002 |
Effect of delayed argatroban treatment on intracerebral hemorrhage-induced edema in the rat.
Topics: Animals; Antithrombins; Arginine; Brain; Brain Edema; Cerebral Hemorrhage; Collagenases; Drug Administration Schedule; Hematoma; Injections; Injections, Intraperitoneal; Male; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Sulfonamides | 2003 |
Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment.
Topics: Animals; Anticoagulants; Arginine; Astrocytes; Brain Edema; Cerebral Hemorrhage; Hematoma; Male; Neutrophils; Pipecolic Acids; Rats; Rats, Wistar; Sulfonamides | 2005 |
Thrombin-induced delayed injury involves multiple and distinct signaling pathways in the cerebral cortex and the striatum in organotypic slice cultures.
Topics: Animals; Anticoagulants; Apoptosis; Arginine; Brain Damage, Chronic; Caspase 3; Caspase Inhibitors; Caspases; Cerebral Cortex; Cerebral Hemorrhage; Corpus Striatum; MAP Kinase Signaling System; Nerve Degeneration; Organ Culture Techniques; Oxidative Stress; Phosphorylation; Pipecolic Acids; Protein Kinase C; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Receptor, PAR-1; src-Family Kinases; Sulfonamides; Thrombin; Time Factors | 2006 |
Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury.
Topics: Animals; Arginine; Brain; Brain Damage, Chronic; Cell Death; Cerebral Hemorrhage; Cycloheximide; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gliosis; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 1; MAP Kinase Signaling System; Microglia; Nerve Degeneration; Neurons; Neuroprotective Agents; Pipecolic Acids; Platelet Aggregation Inhibitors; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombin | 2007 |
Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.
Topics: Animals; Antithrombins; Arginine; Brain Ischemia; Cerebral Hemorrhage; Dose-Response Relationship, Drug; Fibrin; Incidence; Infarction, Middle Cerebral Artery; Intracranial Embolism; Male; Pipecolic Acids; Rats; Rats, Wistar; Recombinant Proteins; Stroke; Sulfonamides; Time Factors; Tissue Plasminogen Activator | 2001 |